Barclays
ARIA

Barclays’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Barclays’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-46,500
Closed -$578K – 7227
2016
Q4 		$578K Sell
46,500
-12,200
-21% -$147K ﹤0.01% 3244
2016
Q3 		$804K Buy
58,700
+4,600
+9% +$46.2K ﹤0.01% 2830
2016
Q2 		$400K Buy
54,100
+40,000
+284% +$300K ﹤0.01% 3388
2016
Q1 		$85K Sell
14,100
-34,400
-71% -$193K ﹤0.01% 4465
2015
Q4 		$291K Sell
48,500
-29,400
-38% -$193K ﹤0.01% 3616
2015
Q3 		$390K Buy
77,900
+5,000
+7% +$38.5K ﹤0.01% 3572
2015
Q2 		$583K Buy
72,900
+8,900
+14% +$78.7K ﹤0.01% 3352
2015
Q1 		$512K Sell
64,000
-182,000
-74% -$1.35M ﹤0.01% 3599
2014
Q4 		$1.48M Buy
246,000
+65,900
+37% +$412K ﹤0.01% 2810
2014
Q3 		$901K Sell
180,100
-128,400
-42% -$750K ﹤0.01% 3453
2014
Q2 		$1.85M Sell
308,500
-1,493,900
-83% -$10.3M ﹤0.01% 2685
2014
Q1 		$14.4M Buy
1,802,400
+1,479,200
+458% +$11.5M 0.02% 895
2013
Q4 		$1.94M Buy
323,200
+177,800
+122% +$960K ﹤0.01% 2709
2013
Q3 		$2.62M Buy
145,400
+92,800
+176% +$1.8M ﹤0.01% 2285
2013
Q2 		$919K Buy
+52,600
New +$932K ﹤0.01% 3488

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Barclays's ARIA Position: Q1 2017 in Review

Barclays sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 17,361 shares — an estimated $216K sold.

Barclays first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $11.6M in Q4 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Barclays reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Barclays sold 17,361 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $216K.
  • Barclays first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Barclays's Ariad Pharmaceuticals Inc position peaked at $11.6M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Barclays's 13F filing for Q1 2017, filed 15 May 2017.